Fiduciary Trust Co. Has $14.45 Million Position in Becton, Dickinson and Company (BDX)

Fiduciary Trust Co. decreased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 8.9% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 73,756 shares of the medical instruments supplier’s stock after selling 7,172 shares during the period. Fiduciary Trust Co.’s holdings in Becton, Dickinson and were worth $14,453,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in Becton, Dickinson and by 8.5% during the 2nd quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock valued at $3,366,809,000 after purchasing an additional 1,353,780 shares in the last quarter. BlackRock Inc. increased its stake in Becton, Dickinson and by 2,427.8% during the 1st quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock valued at $3,034,470,000 after purchasing an additional 15,887,611 shares in the last quarter. State Street Corp increased its stake in Becton, Dickinson and by 3.5% during the 2nd quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock valued at $2,003,834,000 after purchasing an additional 342,873 shares in the last quarter. Northern Trust Corp increased its stake in Becton, Dickinson and by 4.0% during the 2nd quarter. Northern Trust Corp now owns 2,813,937 shares of the medical instruments supplier’s stock valued at $549,028,000 after purchasing an additional 106,966 shares in the last quarter. Finally, Fiera Capital Corp increased its stake in Becton, Dickinson and by 7.1% during the 2nd quarter. Fiera Capital Corp now owns 2,782,146 shares of the medical instruments supplier’s stock valued at $542,825,000 after purchasing an additional 183,372 shares in the last quarter. 86.01% of the stock is owned by institutional investors.

In related news, insider Gary M. Cohen sold 15,044 shares of the stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $200.43, for a total transaction of $3,015,268.92. Following the sale, the insider now directly owns 95,270 shares of the company’s stock, valued at $19,094,966.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Gary M. Cohen sold 15,512 shares of the stock in a transaction on Monday, September 11th. The stock was sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the sale, the insider now directly owns 95,781 shares in the company, valued at $19,517,294.37. The disclosure for this sale can be found here. Insiders have sold 53,187 shares of company stock worth $10,720,847 over the last three months. 1.40% of the stock is currently owned by insiders.

WARNING: This story was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://ledgergazette.com/2017/11/13/fiduciary-trust-co-has-14-45-million-position-in-becton-dickinson-and-company-bdx.html.

A number of research analysts have issued reports on BDX shares. Wells Fargo & Company restated a “positive” rating and set a $235.00 price target (up previously from $225.00) on shares of Becton, Dickinson and in a research note on Tuesday, October 24th. They noted that the move was a valuation call. BidaskClub lowered shares of Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Piper Jaffray Companies restated a “buy” rating and set a $213.00 price target on shares of Becton, Dickinson and in a research note on Tuesday, September 12th. Morgan Stanley upped their price target on shares of Becton, Dickinson and from $205.00 to $245.00 and gave the company an “equal weight” rating in a research note on Friday, November 3rd. Finally, Bank of America Corporation restated a “buy” rating and set a $225.00 price target (up previously from $200.00) on shares of Becton, Dickinson and in a research note on Friday, July 21st. Five investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $213.47.

Shares of Becton, Dickinson and Company (BDX) opened at $219.23 on Monday. Becton, Dickinson and Company has a twelve month low of $161.29 and a twelve month high of $225.23. The stock has a market cap of $49,889.07, a price-to-earnings ratio of 23.10, a P/E/G ratio of 1.72 and a beta of 1.04. The company has a current ratio of 5.56, a quick ratio of 5.01 and a debt-to-equity ratio of 1.48.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.37 by $0.03. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 22.51%. The firm had revenue of $3.17 billion for the quarter, compared to the consensus estimate of $3.14 billion. During the same period in the prior year, the firm posted $2.12 earnings per share. The firm’s quarterly revenue was down 2.0% compared to the same quarter last year. analysts anticipate that Becton, Dickinson and Company will post 10.63 EPS for the current fiscal year.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply